Skip to main content

Table 2 Key base case cost-effectiveness model inputs

From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Input parameters Base case value References
Vaccination   
Duration of vaccine protection Lifetime Assumption
Age at Vaccination (years) 12 Assumption
Vaccine Coverage 100% Assumption
Efficacy: HPV-16/18 (both vaccines) 98.0% [26, 4650]
HPV-16/18 AS04-adjuvanted Vaccine   
Efficacy: Non-vaccine oncogenic HPV types   
   CIN1 47.7% (95% CI: 28.9%, 61.9%) [51]
   CIN2+ 68.4% (95% CI: 45.7%, 82.4%) [25]
HPV-6/11/16/18 vaccine Efficacy: Non-vaccine oncogenic HPV types   [27]
   CIN1 23.4% (95% CI: 7.8%, 36.4%)  
   CIN2+ 32.5% (95% CI: 6.0%, 51.9%)  
HPV-6/11/16/18 Vaccine Efficacy: HPV 6/11 98.0% [50]
Screening   
Screening Coverage   [52]
   Age Range 18 to 69 years  
   Regular (once/ 3 years) 70%  
   Irregular (ages 25, 40, 50) 18%  
   Never 12%  
CIN1 detected (sensitivity) 42% [44, 52, 53]
CIN2/3 detected (sensitivity) 55% [44, 52, 53]
% Positive pap Smear 5% [44, 52, 53]
Cost (2006 CAD)   
HPV-16/18 AS04-adjuvanted vaccine Cost (per dose) $110.97 Assumption
HPV-6/11/16/18 vaccine Cost (per dose) $110.97 Assumption
Genital Warts treatment (per episode) $207.00 [44]
Cytology Test $57.00 [30, 33, 54]
Colposcopy and biopsy $150.00 [30, 33, 54]
CIN1 treatment and follow-up* $843.00 [30, 33, 54]
CIN2/3 treatment and follow-up* $1 414.00 [30, 33, 54]
Cervical cancer stage 1 $11 915.00 [30, 33, 54]
Cervical cancer stage 2 $18 851.00 [30, 33, 54]
Cervical cancer stage 3 $18 851.00 [30, 33, 54]
Cervical cancer stage 4 $25 759.00 [30, 33, 54]
Utility   
No HPV, HPV Infection 1, 1  
CIN1 detected 0.987 [5558]
CIN2/3 detected 0.991 [5558]
Cancer treated 0.727 [5558]
Cancer cured 0.938 [5558]
Genital Warts 0.980 [59]
  1. * Cost calculated assuming that 50% of CIN1 and 100% of CIN2/3 are treated. Follow-up after CIN1/2/3 assumed to include 2 additional cytology tests and colposcopies for all patients.
  2. † Genital warts assumed to cause a decrement of 0.8 in utility across 3 months.